Paige, a NYC-based the leader in computational pathology transforming the diagnosis and treatment of cancer, closed a Series B funding round of $45m.
The round was led by Healthcare Venture Partners with participation from Breyer Capital, Kenan Turnacioglu, and other funds.
The company will use this new capital to drive FDA clearance of its products and expand its portfolio, focusing on cancer pathology, novel biomarkers and prognostic capabilities, and accelerate commercial efforts in the U.S. and expansion in Europe, Brazil, and Canada.
Led by Leo Grady, CEO, Paige builds clinical-grade computational technologies to transform the diagnosis, treatment and biomarker discovery for cancer.
The company has created an AI-native digital pathology ecosystem that enables pathologists to achieve faster throughput and lower cost diagnoses and treatment recommendations.
Additionally, Paige accelerates new biomarker discovery, and is built to generate new insights into pathways and drug efficacy.